Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. more
Time Frame | CHRO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 12.82% | 0.49% | -1.93% |
1-Month Return | 45.57% | -3.1% | -3.69% |
3-Month Return | 64.1% | -8.59% | 0.82% |
6-Month Return | -34.6% | -4.57% | 3.51% |
1-Year Return | -81.2% | -0.94% | 21.91% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | 199.93K | - | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | 138.59K | 209.05K | 391.73K | 2.58M | [{"date":"2020-12-31","value":5.37,"profit":true},{"date":"2021-12-31","value":8.1,"profit":true},{"date":"2022-12-31","value":15.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | 61.35K | (209.05K) | (391.73K) | (2.58M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-340.75,"profit":false},{"date":"2022-12-31","value":-638.53,"profit":false},{"date":"2023-12-31","value":-4204.5,"profit":false}] | |
Gross Margin | 30.68% | - | - | - | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 1.55M | 839.00K | 2.32M | 6.86M | [{"date":"2020-12-31","value":22.64,"profit":true},{"date":"2021-12-31","value":12.23,"profit":true},{"date":"2022-12-31","value":33.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (1.35M) | (839.00K) | (2.32M) | (6.86M) | [{"date":"2020-12-31","value":-135387000,"profit":false},{"date":"2021-12-31","value":-83900000,"profit":false},{"date":"2022-12-31","value":-231816000,"profit":false},{"date":"2023-12-31","value":-686228400,"profit":false}] | |
Total Non-Operating Income/Expense | 691.61K | 243.36K | (280.86K) | (1.04M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":35.19,"profit":true},{"date":"2022-12-31","value":-40.61,"profit":false},{"date":"2023-12-31","value":-149.94,"profit":false}] | |
Pre-Tax Income | (660.58K) | (595.39K) | (2.46M) | (7.38M) | [{"date":"2020-12-31","value":-66058400,"profit":false},{"date":"2021-12-31","value":-59538700,"profit":false},{"date":"2022-12-31","value":-245858900,"profit":false},{"date":"2023-12-31","value":-738079300,"profit":false}] | |
Income Taxes | (1.35M) | (839.00K) | (690.45K) | (6.86M) | [{"date":"2020-12-31","value":-135386700,"profit":false},{"date":"2021-12-31","value":-83899600,"profit":false},{"date":"2022-12-31","value":-69045200,"profit":false},{"date":"2023-12-31","value":-686228400,"profit":false}] | |
Income After Taxes | 693.28K | 243.61K | (1.77M) | (518.51K) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":35.14,"profit":true},{"date":"2022-12-31","value":-255.04,"profit":false},{"date":"2023-12-31","value":-74.79,"profit":false}] | |
Income From Continuous Operations | (660.58K) | (595.39K) | (2.46M) | (7.38M) | [{"date":"2020-12-31","value":-66058400,"profit":false},{"date":"2021-12-31","value":-59538700,"profit":false},{"date":"2022-12-31","value":-245858900,"profit":false},{"date":"2023-12-31","value":-738079300,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (660.58K) | (595.39K) | (2.46M) | (7.38M) | [{"date":"2020-12-31","value":-66058400,"profit":false},{"date":"2021-12-31","value":-59538700,"profit":false},{"date":"2022-12-31","value":-245858900,"profit":false},{"date":"2023-12-31","value":-738079300,"profit":false}] | |
EPS (Diluted) | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
CHRO | |
---|---|
Cash Ratio | 0.35 |
Current Ratio | 0.60 |
Quick Ratio | 0.61 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CHRO | |
---|---|
ROA (LTM) | -412.80% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CHRO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.67 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.67 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CHRO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 4.11 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Chromocell Therapeutics Corporation (CHRO) share price today is $0.965
Yes, Indians can buy shares of Chromocell Therapeutics Corporation (CHRO) on Vested. To buy Chromocell Therapeutics Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CHRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Chromocell Therapeutics Corporation (CHRO) via the Vested app. You can start investing in Chromocell Therapeutics Corporation (CHRO) with a minimum investment of $1.
You can invest in shares of Chromocell Therapeutics Corporation (CHRO) via Vested in three simple steps:
The 52-week high price of Chromocell Therapeutics Corporation (CHRO) is $6. The 52-week low price of Chromocell Therapeutics Corporation (CHRO) is $0.45.
The price-to-earnings (P/E) ratio of Chromocell Therapeutics Corporation (CHRO) is
The price-to-book (P/B) ratio of Chromocell Therapeutics Corporation (CHRO) is 4.11
The dividend yield of Chromocell Therapeutics Corporation (CHRO) is 0.00%
The market capitalization of Chromocell Therapeutics Corporation (CHRO) is $5.18M
The stock symbol (or ticker) of Chromocell Therapeutics Corporation is CHRO